Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 25, 2023
Rise of Antibody-Drug Conjugates: The Present and FutureMythili Shastry, Avantika Gupta, Sarat Chandarlapaty, et al.
Cancer|July 30, 2013
Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifenJeffrey Peppercorn, Erika Hamilton, Paul Kelly Marcom, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging roleMaxwell R Lloyd, Seth A Wander, Erika Hamilton, et al.
Clinical Breast Cancer|October 9, 2013
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancerErika Hamilton, Gretchen Kimmick, Judith Hopkins, et al.
The Lancet. Oncology|May 29, 2018
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b studyRashmi Murthy, Virginia F Borges, Alison Conlin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trialNatalie Dennis, Kyle Dunton, Christopher Livings, et al.
Therapeutic Advances in Medical Oncology|August 14, 2023
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancerMark Pegram, Richard Pietras, Chau T Dang, et al.
Antioxidants & Redox Signaling|April 24, 2002
Serum xanthine oxidase: origin, regulation, and contribution to control of trypanosome parasitemiaJun Wang, Andrew Van Praagh, Erika Hamilton, et al.
Cancer|March 27, 2023
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumorsShubham Pant, Erika Hamilton, Susanna V Ulahannan, et al.
BMC Cancer|May 6, 2022
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United StatesJacqueline Brown, Savannah Scardo, Michael Method, et al.
Pageof 9